Research analysts at Rodman & Renshaw started coverage on shares of CytoDyn Inc (OTC:CYDY) in a research note issued on Thursday, StockTargetPrices.com reports. The firm set a “buy” rating and a $1.60 price target on the stock. Rodman & Renshaw’s price objective suggests a potential upside of 131.88% from the company’s current price.
CytoDyn (OTC:CYDY) traded up 7.46% during trading on Thursday, reaching $0.72. 1,539,804 shares of the company’s stock traded hands. The company’s market capitalization is $89.66 million. The firm’s 50 day moving average is $0.89 and its 200-day moving average is $1.04. CytoDyn has a 12 month low of $0.63 and a 12 month high of $1.57.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
Receive News & Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related companies with MarketBeat.com's FREE daily email newsletter.